Wegovy and Zepbound are part of a wave of obesity medications known as GLP-1 receptor agonists that have soared in popularity ...

Eli Lilly's Zepbound loses CVS coverage to Wegovy, prompting analyst debate on pricing pressures and long-term obesity market ...

Shares in Eli Lilly have weakened after CVS Health, one of the largest pharmacy benefit managers (PBMs) in the US, said it ...

In an internal memo, the World Health Organization signaled its support for anti-obesity drugs like Wegovy and Zepbound, ...

The market for weight loss drugs is white-hot, and competition is heating up fast. This Danish company is already facing a ...

Tirzepatide is now approved for the treatment of obstructive sleep apnea, highlighting the drug class' potential in sleep medicine.

Analysts were rushing to reiterate their conviction in the stock following Thursday’s blow to Zepbound and Lilly shares.

GLP-1 drug prices are falling. That's good news for patients, but perhaps not such good news for pharmaceutical stock ...

CVS drops Lilly's Zepbound for Novo's Wegovy in rebate-driven dealTelehealth partnerships expand access with cheaper ...

The company's experimental once-daily version will become the first oral GLP-1 for chronic weight management, if approved. U.S.-listed shares of Novo added to session gains and were last up 5.72% at ...

NEW YORK (AP) — More U.S. children have died this flu season than at any time since the swine flu pandemic 15 years ago, according to a federal report released Friday. The 216 pediatric deaths ...

RO is a DTP telehealth company that provides nationwide services. The company offers multiple GLP-1 options and has hired a ...